Really, what has happened over the last year we have talked about in previous episodes is that the three insulin manufacturers in the United States, Sanofi, Novo Nordisk, and Lilly have decided that theyre going to have a cap of $35 for all patients, not just Medicare patients, which Inflation Reduction Act does
If side effects prevent dose escalation, your provider may recommend switching to oral tirzepatide, semaglutide, or GLP-Squared to activate different peptide pathways
Semaglutide is under patent protection, with Novo Nordisk as the sole manufacturer of brand-name versions, allowing premium pricing
GLP-1 also refers to a class of medications that are analogous (similar in structure and function) to the GLP-1 that is made naturally in our body
They compound on a per-prescription basis, and testing requirements are generally less rigorous
We accounted for age, sex, BMI, smoking history, chronic steroid usage, and weight change over time